0001127602-22-025018.txt : 20221107
0001127602-22-025018.hdr.sgml : 20221107
20221107160649
ACCESSION NUMBER: 0001127602-22-025018
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221103
FILED AS OF DATE: 20221107
DATE AS OF CHANGE: 20221107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRAZIER KENNETH C
CENTRAL INDEX KEY: 0001181175
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06571
FILM NUMBER: 221365431
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Merck & Co., Inc.
CENTRAL INDEX KEY: 0000310158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 221918501
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
BUSINESS PHONE: 908-740-4000
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
FORMER COMPANY:
FORMER CONFORMED NAME: Merck & Co. Inc.
DATE OF NAME CHANGE: 20091103
FORMER COMPANY:
FORMER CONFORMED NAME: SCHERING PLOUGH CORP
DATE OF NAME CHANGE: 19920703
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-11-03
0000310158
Merck & Co., Inc.
MRK
0001181175
FRAZIER KENNETH C
MERCK & CO., INC.
126 E. LINCOLN AVENUE
RAHWAY
NJ
07065
1
1
Executive Chair
Common Stock
2022-11-03
4
M
0
235000
0
A
935653.063
D
Common Stock
2022-11-03
4
S
0
214617
98.6785
D
721036.063
D
Common Stock
2022-11-03
4
S
0
20383
99.0926
D
700653.063
D
Common Stock
2022-11-04
4
M
0
235000
0
A
935653.063
D
Common Stock
2022-11-04
4
S
0
200190
98.5326
D
735463.063
D
Common Stock
2022-11-04
4
S
0
34810
99.0804
D
700653.063
D
Common Stock - 401(k) Plan
4481.1286
I
By 401(k)
Stock Option (Right to Buy)
53.06
2022-11-03
4
M
0
235000
0
D
2017-05-10
2026-05-09
Common Stock
235000
470769
D
Stock Option (Right to Buy)
53.06
2022-11-04
4
M
0
235000
0
D
2017-05-10
2026-05-09
Common Stock
235000
235769
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Holdings include shares acquired in dividend reinvestment transactions.
Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
/s/ Kelly E. W. Grez as Attorney-in-Fact for Kenneth C. Frazier
2022-11-07